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SUMMARY
Amajor challenge in cancer research is thecomplexity
of the tumor microenvironment, which includes
the host immunological setting. Inspired by the
emerging technology of organ-on-chip, we achieved
3D co-cultures in microfluidic devices (integrating
four cell populations: cancer, immune, endothelial,
and fibroblasts) to reconstitute ex vivo a human tumor
ecosystem (HER2+ breast cancer). We visualized and
quantified the complex dynamics of this tumor-on-
chip, in the absence or in the presence of the
drug trastuzumab (Herceptin), a targeted antibody
therapy directed against the HER2 receptor. We
uncovered the capacity of the drug trastuzumab
to specifically promote long cancer-immune inter-
actions (>50 min), recapitulating an anti-tumoral
ADCC (antibody-dependent cell-mediated cytotox-
icity) immune response. Cancer-associated fibro-
blasts (CAFs) antagonized the effects of trastuzumab.
These observations constitute a proof of concept
that tumors-on-chip are powerful platforms to study
ex vivo immunocompetent tumormicroenvironments,
to characterize ecosystem-level drug responses, and
to dissect the roles of stromal components.
INTRODUCTION
Tumor microenvironments are ecosystems composed of a vari-
ety of cell types (e.g., cancer cells, fibroblasts, immune cells,
endothelial cells) positioned in complicated physicochemical
contexts. It is now well established that understanding the
complexity of the tumor ecosystems and their organizational
principles is crucial, as they play a pivotal role in cancer progres-
sion, metastasis, and response to therapies (Klemm and Joyce,
2015). This complexity is commonly studied using animal
models, usually immunodeficient mice to which human tumors
are xenografted, with 2 major limitations: poor control of all var-
iable factors and the impossibility of addressing questions about
the role of the immune system. In addition, animal experimenta-
tion is long, expensive, and ethically questionable, and the trans-
position of results to humans is still debatable.
Recent advances in microtechnology inspired new strategies
to reproduce ex vivo the complexity of biological systems. For
example, functional units of some organs (e.g., lungs) and
specific biological processes (e.g., angiogenesis) were recon-
stituted by placing human cells in microfluidic devices,
giving rise to the field of organs-on-chip (Huh et al., 2013).
These approaches mimic organ topography, functionality, and
complexity much better than conventional 2-dimensional (2D)
or even 3D culture systems (van Duinen et al., 2015). In the
cancer field, pioneering works reported 3D microarchitectures
on-chip that mimic certain features of the tumor microenviron-
ments, building the basis for the technology of tumors-on-
chip (Bersini et al., 2014; Hassell et al., 2017; Sung and Beebe,
2014; Zervantonakis et al., 2012). In particular, our recent pa-
pers (Businaro et al., 2013; Parlato et al., 2017; Vacchelli
et al., 2015) demonstrated how powerful these devices are in
monitoring cancer-immune interactions. In these previous
studies, the allogeneic nature of the immune cells did not appar-
ently lead to major interferences, presumably because the co-
culture times were too short for a mixed lymphocyte reaction
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(MLR) (Nguyen et al., 2003). Despite this huge potential, so far
the use of tumors-on-chip has been restrained to a few special-
ized laboratories and has not reached the broad community of
cancer research.
To validate the concept that tumors-on-chip could be ex-
ploited to study ex vivo responses to treatments that depend
on the tumor ecosystem and to address oncoimmunology ques-
tions by monitoring complex multi-cell interactions involving im-
mune cells, we chose themodel of HER2+ breast cancer subtype
(with HER2-receptor gene amplification) because of the avail-
ability of a targeted monoclonal antibody against the HER2 re-
ceptor, trastuzumab (brand name Herceptin). Trastuzumab has
been a reference drug for patients with HER2+ breast cancers
for more than a decade, with convincing overall survival benefits
(Marty et al., 2005). It has been proposed that trastuzumab acts
via not only a direct effect on cancer cells (inhibition of prolifera-
tion and induction of programmed cell death) but also an indirect
effect mediated by the innate immune system (antibody-depen-
Figure 1. Reconstitution and Quantitative
Description of an HER2+ Tumor Ecosystem
with Four Cell Populations
(A) The tumor-on-chip approach. At left, a scheme
of the chip, with a central vascular compartment
made of a monolayer of endothelial cells (pink),
2 lateral chambers with 3D collagen I hydrogels
(gray) in which cancer cells (green) and CAFs (red)
are embedded, together with immune cells (blue).
At right, a real image from a representative video is
shown. Scale bar, 50 mm.
(B) Countingmitosis and apoptotic death of cancer
cells. Representative events are shown. To
monitor mitosis, nuclei were live stained using a
far-red nuclear dye (SiR-DNA). To monitor death,
cells were live stained using a green probe,
which detects caspase 3 and 7 activity (CellEvent
caspase-3/7).
(C) CellHunter method to track cancer-immune cell
interactions. The method implies 3 steps: video
acquisition, cell localization, and cell tracking.
dent cell-mediated cytotoxicity [ADCC])
(Arnould et al., 2006; Clynes et al., 2000;
Kute et al., 2012; Varchetta et al., 2007).
In this work, we reconstituted the
HER2+ breast tumor microenvironment
in 3D hydrogels on-chip containing a cen-
tral endothelium compartment. We visu-
alized and quantified the ecosystem dy-
namics (proliferation, apoptosis, motility,
and cancer-immune cell-cell interactions)
over 4 days, according to a defined stro-
mal composition: with or without immune
cells or with or without cancer-associated
fibroblasts (CAFs).
We demonstrated that the presence of
trastuzumab, in addition to inhibiting can-
cer cell proliferation and stimulating can-
cer cell death as expected, increased
cancer-immune interactions and induced
an anti-tumoral ADCC immune response. In addition, we uncov-
ered an inhibitory role for CAFs regarding cancer-immune inter-
actions, supporting the emerging concept of an immune-sup-
pressive role for CAFs in the tumor microenvironment (Costa
et al., 2018; Feig et al., 2013; Givel et al., 2018; Kraman et al.,
2010; Liao et al., 2009; Yang et al., 2016; Zhang and Ertl, 2016)
and suggesting that CAFs may contribute to resistance to
trastuzumab.
RESULTS
Reconstitution of an HER2+ Tumor Ecosystem On-Chip,
Including CAFs and Immune Cells
We designed a microfluidic device for cell co-cultures (called a
chip for short), based on published works (Chen et al., 2017; Lu-
carini et al., 2017; Parlato et al., 2017; Zervantonakis et al., 2012)
(Figure 1A). The chips were microfabricated by soft lithography
using PDMS (polydimethylsiloxane), a silicone rubber that is
Cell Reports 25, 3884–3893, December 26, 2018 3885
biocompatible, gas permeable, and transparent. The chip design
consisted of 5 parallel microchambers (500- to 1000-mm wide,
150- to 200-mmhigh), separated by regularly spacedmicropillars
that allow the confinement of hydrogels by means of a balance
between surface tension and capillary forces. The various cell
types were positioned inside the chips, mimicking their original
in vivo architecture in tumors.
Cancer cells (the HER2+ breast cancer BT474 cell line), can-
cer-associated fibroblasts (the breast CAF cell line Hs578T),
and immune cells (PBMCs [peripheral blood mononuclear cells]
from healthy donors) were embedded into 3D biomimetic hydro-
gels (made of collagen type I at 2.3mg/mL, themajor component
of the extracellular matrix [ECM]), inside the 2 inner lateral cham-
bers. To compare conditions with and without CAFs within the
same chip, the left gel chamber waswithout CAFs, while the right
gel chamber was with CAFs. The 2 outer lateral chambers were
used as medium reservoirs. This work was focused on the ef-
fects of CAFs and immune cells; however, endothelial cells
were always included since in vivo they contribute to shaping
the biochemical environment by secreting a variety of cytokines
and other soluble factors (Buchanan et al., 2012; Lee et al.,
2015). Endothelial cells (primary human umbilical vein endothe-
lial cells [HUVECs]) were grown as 2D monolayers in the central
chamber, as previously reported (Zervantonakis et al., 2012).
For simplicity, the majority of co-cultures and observations
were performed without adding perfusion in this vessel compart-
ment. Considering that 3D cell co-cultures were achieved in
microfluidics devices and that the literature extensively uses
Figure 2. Confocal Imaging of the Reconsti-
tuted Tumor Ecosystem
(A) The various cell types were differentially live
stained with CellTrace dyes before seeding inside
the tumor-on-chip. The confocal image recon-
struction shows the 3D positioning of BT474 can-
cer cells (green), Hs578T CAF cells (red), PBMC
immune cells (blue), and HUVECs (violet).
(B) This magnified 3D view shows physical cell-cell
interactions between BT474 cancer cells (green)
and immune cells (blue).
(C) This magnified 3D view shows a CAF cell (red),
which is contacting several cancer cells (green)
and immune cells (blue).
the organ-on-chip terminology even for
systems without perfusion, we adopted
the tumor-on-chip terminology for our
approach.
These tumors-on-chip were visualized
by high-content video-microscopy (multi-
positioning, multi-colors, 2- to 120-min
time intervals) for 4–5 days (Video S1). To
discriminate cancer cells fromCAFs, the fi-
broblastswerepre-stained in redwitha live
dye (CellTrace Yellow reagent) (Video S2).
In addition, to quantitatively describe the
tumor ecosystem,we implementedappro-
priate methods to measure on-chip prolif-
eration, apoptoticdeath,andcell-cell inter-
actions (Figures 1B and 1C). To monitor proliferation, nuclei were
live stained using a far-red nuclear dye (SiR-DNA), which allows
for the identification and counting of mitotic events (Video S3).
To monitor cell death, apoptotic cells were identified using a
green probe detecting caspase 3 and 7 activity (CellEvent
caspase-3/7) (Video S4). Cells undergoing apoptosis, in addition
to emitting green fluorescence, also showed a change in
morphology. The overall observation of hundreds of videos re-
vealed extremely rich and complex cell-cell interactions involving
immune cells (Video S5). Using the ad hoc-designed CellHunter
automated method (Biselli et al., 2017; Parlato et al., 2017), we
tracked the cell dynamics within the co-cultures and measured
the interaction times with each immune cell for each cancer cell
(Figure 1C), thus providing a high-content description of the can-
cer-immune cell interactions inside the reconstituted tumor
ecosystem. The relative positioning and morphologies of the
different cell populations were investigated by live snapshot
confocal microscopy; cancer cells, immune cells, and fibroblasts
are distributed along the z dimension of the collagen gel, and
several cell-cell contacts occur in this true 3D ecosystem. The
endothelial cells create vertical barriers, although not continuous
ones, at the interfaces between the endothelium channel and
the collagen gels (Figure 2).
Wemodulated this experimental setting by adding or removing
specific cellular components (CAFs and immune cells) and the
drug trastuzumab, the invariable components being cancer and
endothelial cells; in this way, we analyzed 8 different co-culture
conditions, which are summarized in Figure 3.
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Pro-invasive Effects of CAFs in the HER2+ Tumor
Ecosystem
CAFs promote the motility and invasion of cancer cells by a mul-
tiplicity of possible mechanisms (Attieh et al., 2017; De Wever
et al., 2004; Gaggioli et al., 2007; Glentis et al., 2017; Goetz
et al., 2011; Labernadie et al., 2017). The heterogeneity of
CAFs was very recently characterized in breast and ovarian can-
cers, identifying at least 4 different CAF subpopulations, referred
to as CAF-S1–CAF-S4, with distinct properties and levels of acti-
vation (Costa et al., 2018; Givel et al., 2018). By using the same
markers as in the aforementioned studies (epithelial cell adhe-
sion molecule [EPCAM], fibroblast activation protein [FAP],
CD29, platelet-derived growth factor subunit B [PDGFB], alpha
smooth muscle actin [aSMA]), we characterized by fluores-
cence-activated cell sorting [FACS] the molecular identity of
our CAF cell model, the Hs578T cell line, and found that it corre-
sponds to the CAF-S1 subtype (Figure 4A). Pathway enrichment
analysis had previously pointed out that genes upregulated in the
CAF-S1 subset were involved in cell adhesion, ECM organiza-
tion, and immune response; in particular, the CAF-S1 subset
was shown to specifically promote immunosuppression through
a multistep mechanism (Costa et al., 2018; Givel et al., 2018).
We questioned whether the presence of Hs578T CAF-S1 cells
modulated cancer cell motility within the collagen type I matrix
in the tumor-on-chip. We measured the movements of the
BT474 cancer cells inside the tumors-on-chip by tracking these
cells with CellHunter, in the presence or the absence of CAFs
(conditions 3, 4, 7, and 8). Figure 4B shows representative
results from 1 experiment (n tracks per condition >600), which
were reproduced in 3 independent experiments (Figure S1).
Similar results were obtained with manual tracking (n cells per
condition = 45–65) (Figure S2).
The presence of CAFs stimulated the velocities of BT474 cells,
in a robust and highly reproducible manner, both in the presence
Figure 3. Experimental Design
(A) Summary of co-culture conditions.
(B) Experimental setting. The chips have a central
endothelium compartment, where HUVECs are
seeded (violet), and 2 gel compartments (gray),
where BT474 cancer cells (green) are embedded,
with or without Hs578T CAF cells (red) and PBMC
immune cells (blue), depending on the conditions.
To compare conditions with and without CAFs, the
left gel chamber was without CAFs, and the right
gel chamber was with CAFs. To compare condi-
tions with and without PBMC immune cells, par-
allel chips were used in the same experiment. To
compare conditions with andwithout trastuzumab,
the drug was added at the beginning of the co-
cultures in the medium of all 3 chambers without
gels: the endothelium central chamber and the 2
outer lateral chambers. Video-microscope acqui-
sitions were initiated 3–24 hr after the start of
co-culture.
and the absence of trastuzumab (20%
increase) (Figures 4B, S1, and S2). The
addition of trastuzumab led to a modest
but statistically significant increase in the velocities of BT474
cells, both with and without CAFs (Figures 4B, S1, and S2). In
our ecosystem, the interactions between CAFs and BT474 can-
cer cells were rare and transitory (Video S2), which argues
against direct pulling mechanisms by the highly motile CAFs
on sluggish cancer cells and suggests the existence of long-
range mechanisms of communication, such as via secreted
molecules or ECM remodeling.
Direct Visualization of Trastuzumab Effects on the
HER2+ Tumor Ecosystem
Trastuzumab is expected to specifically affect the growth of cells
overexpressing the HER2 receptor. In standard 2D cultures, we
verified that trastuzumab did inhibit the growth of HER2+ BT474
cells, but not that of the luminal MCF7 breast cancer cell line
(Figure S3). The drug was used at a 10-mg/mL concentration,
which likely corresponds to a clinically relevant range since it is
on the same order of magnitude as the median concentration
measured in the plasma of trastuzumab-treated patients
(60 mg/mL) (Jamieson et al., 2009). This concentration was satu-
rating since the half-maximal inhibitory concentration (IC50) for
the antiproliferative effects of trastuzumab on BT474 cells is
1.18 mg/mL (Shim et al., 2012). We showed that as a negative
control, as expected, 10 mg/mL trastuzumab did not have any
impact on the 2D growth of CAFs or HUVECs (Figure S3).
When 10 mg/mL trastuzumab was added to the HER2+ tumor-
on-chip medium (in central and 2 outer chambers), we observed
a cytostatic effect, evaluated as a reduction (0.4-fold) in the per-
centage of BT474 mitoses per day (Figure 5A). Without the drug,
the BT474 cancer cell population doubling time on-chip was
approximately 10-fold slower than in 2D (10–20 days versus
1–2 days). We speculate that the reduced rate may be due to
the fact that the cells are embedded in the gel and that
they must divide in a ‘‘real 3D’’ context. Of note, while very
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heterogeneous, the estimated breast tumor doubling times in vivo
in patients are on the order of tens or hundreds of days (Heuser
et al., 1979; Yoo et al., 2015).
In addition, trastuzumab had a cytotoxic effect, evaluated as an
increase (2.5-fold) in the percentage of apoptosis of BT474 cells
per day (Figure 5B). This mild cytotoxic effect of trastuzumab (up
to 5% apoptosis per day) is in agreement with previous data ob-
tained by FACS on 2D BT474 cultures (Diermeier-Daucher et al.,
2011; Nahta et al., 2004). As a consequence, the tumor growth,
calculated by subtracting the apoptosis rate from the mitosis
rate, was impaired by the presence of trastuzumab (Figure 5C).
Figure 4. Characterization of the Hs578T CAF
Cell Line
(A) CAF-S1 identity of the Hs578T cell line. Using flow
cytometry analysis, Hs578T cells were first gated
based on forward (FSC-A) and side (SSC-A) scatters
(measuring cell size and granulosity, respectively) to
exclude debris. Single cells were next selected based
on SSC-A versus SSC-W parameters. Dead cells were
excluded based on their positive staining for live/dead
(for intracellular staining) or DAPI (for surface staining).
Cells were next examined using 1 epithelial marker
(EPCAM) and 4 CAF markers (aSMA, CD29, FAP, and
PDGFB, the last 2 both intracellular and at surface, as
indicated). Blue lines are isotype controls, while red
lines are staining with specific antibodies. Hs578T
cells are clearly EPCAM, aSMA+, CD29+, FAP+, and
PDGFB+.
(B) Pro-invasive effects of CAFs in the HER2+ tumor
ecosystem. Velocity of BT474 cancer cells was
measured for the indicated conditions. Each point
represents the track of a cancer cell. The median
values are shown by red bars and explicitly written
above the points. Results from 1 representative
experiment. Number of tracks n > 600 per condition.
*p < 0.05, **p < 0.001, ***p < 0.0001; ns, not significant,
using Kolmogorov-Smirnov tests.
In the majority of the experiments pre-
sented in this work, the overall cell density
was kept moderate (1 3 106 cells/mL for
cancer cells, 0.25 3 106 cells/mL for CAFs,
5 3 106 cells/mL for PBMCs) to maintain
compatibility with cell dynamics quantifica-
tions.Moreover, the proportion of the various
cell types (roughly 25 CAFs and 500 immune
cells for 100 cancer cells) reflected the in vivo
situation, as assessed by FACS analysis on
dissociated breast tumor samples. Our
FACS measurements indicated a median
2.3:1 ratio for immune cells versus cancer
cells and a median 1:5.8 ratio for CAFs
versus cancer cells (Table S1).
In these conditions, with a local immune
cell-to-cancer cell ratio in the range of
2:1–5:1, the presence or absence of immune
cells or of CAFs did not have a noticeable
impact on mitosis, apoptosis, and tumor
growth rates (Figures 5A–5C). This was
somewhat surprising since, in the presence of trastuzumab,
the addition of immune cells (PBMCs) was expected to increase
the apoptotic death of BT474 cancer cells, which is consistent
with ADCC. We reasoned that ADCC efficacy may require high
immune cell density. When we increased the immune cell-to-
cancer cell ratio to 25:1, we did not observe any effect on the
apoptosis rate of cancer cells as compared to the conditions
without or with low PBMC density in the absence of trastuzu-
mab, but we did observe a massive apoptotic death of BT474
cancer cells in the presence of trastuzumab (Figure 5D; Video
S6). This demonstrates that we could recapitulate and directly
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visualize on-chip the trastuzumab-induced ADCC (i.e., a drug
response that depends on the immune system). Moreover, these
results suggest that in vivo, the local density of infiltrating im-
mune cells may modulate the ADCC response to trastuzumab.
The presence of CAFs slightly inhibited the trastuzumab-induced
ADCC, suggesting a potential immunomodulation effect medi-
ated by CAFs (Figure 5D, compare conditions 7 and 8).
Antagonist Immunomodulation Effects of Trastuzumab
and CAFs in the HER2+ Tumor Ecosystem
Next, we analyzed the effects of trastuzumab on cancer-immune
cell interactions. To do so, for each cancer cell, we measured all
Figure 5. Trastuzumab Effects on HER2+
Tumor Ecosystem, Depending on Stromal
Composition (Immune Cells and CAFs)
(A) Percentage of BT474 cells undergoing mitosis
per day of observation.
(B) Percentage of BT474 cells undergoing
apoptotic death per day of observation. Right: a
representative image at day 1 of co-culture shows
very few dying cells (green) for condition 7.
(C) Calculated percentage of tumor growth per day
of observation.
(D) Percentage of BT474 cells that died for
apoptosis after 48 hr of co-culture when the im-
mune cell-to-cancer cell ratio was increased to
25:1. The magnified image shows the paired
quantifications for each experiment (same PBMC
donor), without and with CAFs. Right: a represen-
tative image at day 1 of co-culture shows many
dying cells (green) for condition 7.
Mitotic and apoptotic events were counted on
the video images from 4 to 5 independent experi-
ments. For clarity, the same apoptosis results
for conditions 1, 2, 5, and 6 were reported twice in
(B) and (D). Number of cells (n) = 200–500 per
condition per experiment. The bars show
means ± SEMs. *p < 0.05, **p < 0.001, ***p <
0.0001; ns, not significant, using unpaired Student
t test, except for the magnification in (D), for which
a paired t test was used. Scale bars, 50 mm.
of the interaction times with the surround-
ing immunecells during the videoobserva-
tions (typically 3 days), using our Cell-
Hunter method (Figure 1C). Interaction is
defined as a situation inwhich the distance
between the center of a cancer cell and the
center of an immune cell is less than twice
the sum of the radii of the 2 cells.
The overall analysis of interactions, in 3
independent experiments, with 3 different
PMBC donors, showed clear tendencies;
the presence of trastuzumab appears to
increase mean and maximum interaction
times, while CAFs appear to decrease
mean and maximum interaction times
(Figure S4).
To better untangle these antagonist ef-
fects, we studied the time course impact
of adding trastuzumab on an established tumor ecosystem (with
CAFs). After 16 hr of co-cultures, moderate flow (1 mL/min) was
applied for 1.5 hr with a syringe pump system to replace the orig-
inal medium (without the drug) with medium containing trastuzu-
mab (Figure 6A). The cancer-immune interaction times (basal me-
dianvalue=30min)slowly increasedupon theadditionof thedrug,
up toa2.1-fold increaseat16–20hrafter drug injection (Figure6B).
The analysis of the distributions of cancer-immune interaction
times before and after injection of the drug showed that trastuzu-
mab increases the frequency of interactions in the range of
50–125 min (Figure 6C). Shorter interactions may include random
collisions and HER2-independent cancer-immune contacts.
Cell Reports 25, 3884–3893, December 26, 2018 3889
We re-analyzed the parallelized tumor-on-chip experiments
(without flow) with and without drug and with and without
CAFs (experimental setting described in Figure 3B), separately
considering ‘‘short’’ interactions (<50 min) and ‘‘long’’ interac-
tions (>50 min). Figure 7A shows representative results from 1
experiment, which were reproduced in 3 independent experi-
ments, using immune cells from different donors (Figure S5). In
the absence of CAFs, the treatment with trastuzumab stimulated
the long cancer-immune interactions, but it did not significantly
affect the short cancer-immune interactions (Figure 7A, left).
Trastuzumab did not stimulate cancer-immune interactions
when MCF7 breast cancer cells (not HER2+) were used (Fig-
ure 7B), supporting the notion that the observed effects are
indeed a consequence of trastuzumab binding the HER2 recep-
tor. The presence of Hs578T CAFs, which we showed as repre-
senting the CAF-S1 subtype, inhibited the capacity of trastuzu-
mab to stimulate long cancer-immune cell interactions (Figures
7A and S5, right), arguing that CAF-S1 cells, by participating in
immunomodulation, may contribute to trastuzumab resistance.
DISCUSSION
Models have always been of central importance in science since
they make a particular part or feature of a complex system easier
to understand, define, quantify, visualize, or simulate, by refer-
encing it to existing and commonly accepted knowledge. In this
work, we report how to build an experimental model of the tumor
ecosystem by using its different ‘‘bricks.’’ While the chip platform
design is based onpreviouswork (Chen et al., 2017; Lucarini et al.,
2017; Parlato et al., 2017; Zervantonakis et al., 2012), we provide
here a significant step forward by simultaneously introducingmul-
tiple types of cells (cancer, immune, endothelial, and fibroblasts)
and combining themicroengineered cancermodel with advanced
live imaging and automated image analysis, allowing high-
throughput trackingat the single-cell level andmassivequantifica-
tions of cell-cell contacts on-chip. The biological relevance of our
tumor microenvironment model is proved by the fact that we did
recapitulate ex vivo complex system-level behaviors previously
described in in vivo studies, suchas the pro-invasive and immuno-
modulation roles of CAFs, the anti-tumoral ADCC immune
response, and the 2modes of action of trastuzumab (direct action
on cancer cells and indirect action via the immune system).
This tumor-on-chip model could be used for basic studies
focusing on the tumor microenvironment and for drug preclinical
testing within immunocompetent settings. In the era of emerging
immunotherapies for cancer (Chen and Mellman, 2017), the
technological development of standardized tumors-on-chip
could be very valuable to study new oncoimmunotherapies, to
increase their efficacy, and to understand the mechanisms of
resistance. These tumor-on-chip platforms will be complemen-
tary to organotypic tumor spheroids (Jenkins et al., 2018) in
that they will provide 2 specific advantages: (1) controllability
of each ecosystem parameter (e.g., cell density, ratio between
cell types and relative positions, specific cell subsets, local oxy-
gen content, ECM features, vascular perfusion) and (2) direct
visualization of cellular dynamics (e.g., proliferation, death,
cell-cell interactions, motility) and of their modulations by drugs
and ecosystem parameters.
Figure 6. TrastuzumabPromotes LongCan-
cer-Immune Interactions
(A) Experimental setting. Tumors-on-chip with all 4
cell populations were put under perfusion using a
syringe pump. Visualization was started after 12 hr
of co-cultures without flow. At 16 hr, 1 ml/min flow
(corresponding to a very moderate 0.03 dyn/cm2
shear stress) was applied for 1.5 hr in the 3
chambers without gels to replace 90 mL of the
original medium (without drug) with medium con-
taining trastuzumab (10 mg/mL). Flow was then
stopped, and visualization was continued up to
3 days.
(B) Kinetics of cancer-immune interactions before
and after trastuzumab injection. For each BT474
cancer cell, the mean interaction time (defined as
the average of the 100 longest interaction times of
the cancer cell with several immune cells) was
measured and plotted as 1 point in the graph, using
time windows of 4 hr. The median values are
shown by red bars and explicitly written above the
points. Number of cancer cells n > 180 per time
windows. *p < 0.05, **p < 0.001, ***p < 0.0001; ns,
not significant, using Kolmogorov-Smirnov tests.
(C) Distribution of cancer-immune interactions
before (12–16 hr) and after (24–36 hr) trastuzumab
injection.
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Here, we show that the tumor-on-chip approach turned out to
be extremely informative to recapitulate complex features of
CAF biology, providing direct visual hints to better understand
the crucial interplay of CAFs with both cancer cells (for motility
within a matrix) and immune cells (for immunomodulation). The
CAF model (Hs578T) used in this work corresponds to the
CAF-S1 subtype. In patient samples, CAF-S1 cells were shown
to promote an immunosuppressive environment, with accumula-
tion of FOXP3+ T lymphocytes (Treg) and a concomitant reduc-
tion in cytotoxic CD8+ T lymphocytes in breast and ovarian can-
cers (Costa et al., 2018; Givel et al., 2018). We provide a direct
ex vivo visualization of the capacity of immunosuppressive
CAF-S1 cells to downmodulate the interactions of cancer cells
with PBMCs, which are mainly composed of lymphocytes (T
cells and B cells), natural killer (NK) cells, and monocytes. Even
though in this study we could not define the exact identity of
the immune cells contacting the cancer cells, since the
morphology features are not sufficient to discriminate among
the immune cell types, we anticipate that immunocompetent tu-
mors-on-chip will be valuable tools to address questions about
the immunosuppressive mechanisms of CAFs.
In addition, our findings provide direct visual evidence for the
immune-dependent mechanism of action of trastuzumab: by
binding to the overexpressed HER2 receptors on the cancer
cell surface, the antibody creates multiple binding sites for Fc re-
ceptors that are present on the surface of several immune cell
subtypes, including NK cells, B lymphocytes, dendritic cells,
and macrophages (Hudis, 2007). This trastuzumab-dependent
Figure 7. Antagonist Immunomodulation
Effects of Trastuzumab and CAFs in the
HER2+ Tumor Ecosystem
(A) Impact of trastuzumab and CAFs on cancer-
immune interactions. The cancer-immune in-
teractions were classified in 2 categories: short
(<50 min) and long (>50 min). For each BT474
cancer cell, the mean interaction time was
measured and plotted as 1 point in the graph. The
median values are shown by red bars and explicitly
written above the points. Number of cancer cells
n > 460 per conditions. *p < 0.05, **p < 0.001, ***p <
0.0001; ns, not significant, using Kolmogorov-
Smirnov tests.
(B) Trastuzumab does not stimulate the physical
interactions between MCF7 cells and immune
cells. The tumors-on-chip were generated with
MCF7 cells (not HER2+) instead of BT474 cells
(HER2+).
stimulation in cancer-immune interac-
tions correlated with a stimulation of can-
cer apoptosis, via ADCC, provided that
immune cells were at high density.
A limitation of this HER2+ tumor-on-
chip is the short-term viability of PBMC
immune cells. By counting the immune
cells that underwent apoptosis during
the time course of experiments, we esti-
mated that roughly half of the PBMCs
were dead after the 4-day co-cultures. Nevertheless, the obser-
vation time window of a few days was sufficient to visualize and
discover some specific features associated with the presence of
trastuzumab, immune cells, and CAFs.
Another limitation is the use of allogeneic immune cells that
can in principle trigger a major histocompatibility complex
(MHC) class I-dependent immune response. However, the incu-
bation time of our co-cultures with immune cells was presum-
ably too short to allow allogeneic reactions to take place; for
example, a MLR typically starts after 3 days and is usually
measured at 5 days of co-cultures (Nguyen et al., 2003). We
consider that the reproducibility of the results with immune cells
originating from different donors is a good control. Exploiting
the tools and methods developed for this work, it will be
possible in the near future to move toward autologous cell
models, including primary cells from patients. Since the volume
of the microchambers is just a few microliters, tumors-on-chips
require an extraordinarily low amount of live cells (in the range of
a few thousand), which makes the use of fresh patient-derived
samples feasible.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell culture
The HER2+ cell lines from ductal carcinoma (BT474, ATCC, #HTB-20), Luminal A adenocarcinoma (MCF7, ATCC, #HTB-22) and the
cancer associated fibroblasts (Hs578T, ATCC, #HTB-126) were cultured in high-glucose DMEM (GE Healthcare, #SH30081.01)
supplemented with 10% fetal bovine serum (FBS, Biosera), 1%Penicillin/Streptomycin (GIBCO), 1% glutamine (GIBCO). The human
umbilical vein endothelial cells (HUVEC, Lonza, #C2517A) were cultured in EBM-2 medium (Lonza, #CC-3156) supplemented with a
cocktail of growth factors (Lonza, #CC-4176): hEGF, hydrocortisone, GA-1000 (Gentamicin, Amphotericin-B), FBS 2%, VEGF, hFGF-
B, R3-IGF-1, Ascorbic acid, Heparin. All cell lines were systematically tested to exclude mycoplasma contamination using a qPCR-
based method (VenorGem Classic, BioValley, #11-1250) and authenticated by SRT profiling (GenePrint 10 system, Promega,
#B9510). PBMCs were isolated from fresh blood in heparinized tubes from healthy donors by density gradient centrifugation
using Lymphoprep (Axis-Shield), according to the local ethical guidelines on experimentation with human samples. Trastuzumab
(Herceptin 150 mg) was purchased from Roche. Analysis of tumor samples was performed according to the relevant national
law on the protection of people taking part in biomedical research. Human experimental procedures were approved by the Institu-
tional Review Board and Ethics committee of the Institut Curie Hospital group (approval February 12th, 2014) and CNIL (Commission
Nationale de l’informatique et des Liberte´s) (N approval: 1674356 delivered March 30th, 2013).
METHOD DETAILS
Microfluidic devices
The PDMS microfluidic devices were fabricated at the CNR-IFN facility using standard soft-lithography methods. Details of design
andmicrofabrication procedures were reported elsewhere (Chen et al., 2017; Lucarini et al., 2017; Parlato et al., 2017; Zervantonakis
et al., 2012).
Preparation of tumors-on-chip
Themicrofluidic devicewas first sterilized inUV-oven (365 nmwavelength) for 30min andwas coatedwith 10 mg/mLhuman fibronectin
(Sigma, # F0895) overnight at 37C, 5% CO2. The microfluidic device was rinsed with PBS and then dried for at least 5 hr at room
temperature in a sterile room. Cells were included in hydrogels of bovine collagen I (PureCol, Advanced Matrix, #5005) at a final con-
centration of 2.3 mg/mL, inMEMmedium (Sigma Aldrich, #M0275), containing 0.28%NaHCO3 (pH = 8) to adjust the final pH to 7. The
targeted final density of BT474, MCF7, Hs578T, PBMCs in gels were respectively 1x106 cells/mL, 1x106 cells/mL, 0.25x106 cells/mL,
and5x106cells/mL.HUVECswere loaded in thecentral chamberat adensityof 5x106cells/mLand reachedconfluence to formamono-
layer approximately 24 hr after seeding. Commonmedium (EBM-2with supplements) was loaded in the 2most external chambers and
never changed to avoid dilution effects.
Live cell staining
When indicated, fibroblasts were stained with CellTraceTMYellow (Thermofisher #C34567), endothelial cells with CellTraceTMViolet
(Thermofisher #C34557), cancer cells with CellTraceTMCFSE (Thermofisher #C34554), immune cells with CellTraceTMFar Red
(Thermofisher #C34564). Cells were trypsinized and re-suspended in solution containing 10 mM dye in PBS. Cells were then
incubated 30 min at 37C, 5% CO2, washed in PBS and loaded in the tumors-on-chip. Cell-event (CellEvent Caspase-3/7 Green
Detection Reagent Thermofisher, #C10423) and siR-DNA (Spirochrome) were added to the chip medium at working concentrations
of 6 mM and 1 mM, respectively, to follow live apoptosis and to stain nuclei.
Live microscopy
Time-lapse videos were acquired interchangeably with two invertedmotorized Leica video-microscopes, both equipped with motor-
ized stage, 37C incubator and CO2 controller, using 10x objectives. The first microscope was a Leica DMIRE2 with a Coolsnap HQ2
camera and illumination by mercury Osram lamp at 103 W. The second microscope was a Leica DMi8 with a Retiga R6 camera and
illumination by Lumencor SOLA SE 365. The H2O saturated atmosphere was obtained by adding wet (sterilized) sponges in close
contact with the chips in the incubator. We also added PDMScovers on top of the chips in order to avoid evaporation. The automated
imaging system was controlled by the software Metamorph (Universal Imaging). For fluorescence acquisitions, images were taken
every 2 hr. Transmission imageswere taken every 2 hr, 5min or 2min. The number of positions taken per chip varied from 4 to 12. Day
0 corresponds to the day of the beginning of the co-culture. We started observation under the microscope after 3-24 hr, for 3 days.
For confocal imaging we used a Leica SP8 confocal microscope with a 25X water immersion lens (NA: 0.95, WD: 2.4mm); the total
scanning depth was 200 mm with 3 mm in z-step. The captured images were reconstructed in 3-D using software LAS AF.
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Image analysis
The mitotic and apoptotic events were counted by eye on the computer screen, identifying the division of cells in the red channel
and the appearance of newly apoptotic cells in the green channel. These events have been normalized by the initial number of cells
at day 1. For each experiment and each condition, 3 to 8 positions were counted.
TheCellHunter trackingmethod (Biselli et al., 2017; Parlato et al., 2017) can be divided into two sections: a first block devoted to the
differential localization of cells in the image and a second block committed to cell tracking. As pictured in Figure 1C, cell localization is
performed by implementing a Circular Hough Transform (CHT) (Davies, 2004) for each frame image in the video. Differential locali-
zation is obtained by using different target object radii (4 mm for PBMCs and 13 mm for cancer cells). The second block implements
cell tracking. In our application, the clear difference in dimension between immune and cancer cells as well as a not so high cell den-
sity in the image allowed for tracking using aConstrained Proximity Tracking (CPT) algorithm. Proximity tracking constructs a track by
linking a cell in a frame i with the closest cell in the frame i+1, within a maximum distance (radius of the dashed circle pictured in Fig-
ure 1C). However, due to the diversified motility characteristics of the two tracked populations of cells, different distances have been
considered: 39 mm for PBMCs (with high expected motility, this value is about 10 times the radius of the PBMC cell) and 13 mm for
cancer cells (with moderately lower motility, the value is equal to the tumor cell radius). Of course, when no cells fall within the
maximum distance from the given cell (missing tracking) or two different cells are going to be linked to the same cell (conflictual
tracking), then the track stops. To solve for unavoidable track splitting phenomena, track gaps procedure has been also considered
by allowing missing tracking for at most 10 min. Cell trajectories are then used to conduct a statistical analysis of the physical inter-
actions between PBMCs and cancer cells. We considered two different temporal descriptors, the mean (Tavg) and the maximum time
of interactions (Tmax). These descriptors are estimated from the ‘time of interaction’ parameter that records the list of all the interac-
tions of a single cancer cell with all the PBMCs using the following procedure: i) For each cancer cell, we identify the starting and the
ending frames within which the center of a given PBMC is close to the center of the cancer cell for less than twice the sum of radii of
the two cells. ii) The difference between the ending and the starting frames denotes an ‘interval of interaction’. By considering all the
PBMCs, we collect a list of intervals of interactions for each cancer cell and estimate the so called time of interaction. iii) The
maximum interval of interaction, Tmax, for each cancer cell, represents one of the two statistical descriptors used for the analysis
of interaction. iv) To compute the average time of interaction, Tavg, first, we sort in decreasing order all the intervals of interaction
for each cancer cell; then, we compute the Tavg only considering the first 100 intervals (corresponding to the 100 longest intervals
of interaction).
Flow Cytometry
For surfaceand intracellularmarker staining, cellswereanalyzedbyflowcytometry on theLSRFORTESSAanalyzer (BDbiosciences), as
previously described (Costa et al., 2018). The following antibodies were used to stain the cells in suspension: anti-EpCAM-BV605
(BioLegend, #324224), anti-CD31-PECy7 (BioLegend, #303118), anti-CD45-APC-Cy7 (BD Biosciences, #BD-557833), anti-CD235a-
PerCP/Cy5.5 (BioLegend, #349109), anti-CD29-Alexa Fluor 700 (BioLegend, #303020), anti-FAP (primary antibody, R&D Systems,
#MAB3715), anti-PDGFRb-PE (BioLegend, #323606), anti-SMA-Alexa Fluor 594 (R&D Systems, #IC1420T-025). We conjugated FAP
antibody with fluorescent dye Zenon APC Mouse IgG1 labeling kit (ThermoFisher Scientific, #Z25051). Data analysis was performed
using FlowJo version X 10.0.7r2.
QUANTIFICATION AND STATISTICAL ANALYSIS
Graphs were created and statistical analysis was performed using Graphpad Prism (v7.0). p values less than 0.05 were considered
significant. The statistical details (number of experiments, number of cells or tracks, median or mean) can be found in each figure
legend. For cell tracking analysis, the data distributions were assessed by Shapiro-Wilk tests and resulted not normal. Therefore me-
dians were shown and nonparametric Kolmogorov-Smirnov tests were used to evaluate significant differences between groups.
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